董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Samuel E. Navarro | 男 | Director | 68 | 5.95万美元 | 未持股 | 2017-09-30 |
| Gregory D. Casciaro | 男 | Director | 68 | 5.58万美元 | 未持股 | 2017-09-30 |
| R. Michael Kleine | 男 | Director | 70 | 5.40万美元 | 未持股 | 2017-09-30 |
| Julian N. Nikolchev | 男 | President, Chief Executive Officer, and Director | 63 | 104.96万美元 | 未持股 | 2017-09-30 |
| Michael A. Bates | 男 | Director | 66 | 9.22万美元 | 未持股 | 2017-09-30 |
| Thomas A. Afzal | 男 | Director | 66 | 7.68万美元 | 未持股 | 2017-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Liam J. Burns | 男 | Vice President, Worldwide Sales and Marketing | 51 | 53.39万美元 | 未持股 | 2017-09-30 |
| Gregory P. Watson | 男 | Vice President, Operations | 61 | 未披露 | 未持股 | 2017-09-30 |
| Julian N. Nikolchev | 男 | President, Chief Executive Officer, and Director | 63 | 104.96万美元 | 未持股 | 2017-09-30 |
| Thomas J. Palermo | 男 | Chief Operations Officer | 55 | 47.09万美元 | 未持股 | 2017-09-30 |
| Robert Y. Newell | 男 | Vice President, Finance and Chief Financial Officer | 69 | 36.20万美元 | 未持股 | 2017-09-30 |
| Robert Y. Newell | 男 | Vice President, Finance and Chief Financial Officer | 69 | 未披露 | 未持股 | 2017-09-30 |
董事简历
中英对照 | 中文 | 英文- Samuel E. Navarro
-
Samuel E. Navarro，2014年3月以来，他曾一直担任我们的董事会成员。2008年10月以来，他一直担任Gravitas Healthcare公司（为医疗技术公司提供战略咨询服务）的管理合伙人。从2005年9月到2008年10月，他曾担任Cowen & Co.（位于纽约）的董事总经理，以及他们的医疗技术投资银行项目负责人，领导高级人团队，并负责建立所有产品类别（并购、咨询和融资服务和产品）的特许经营。从2001年到2005年，他曾任职The Galleon Group，经营the Galleon Healthcare Fund，担任高级投资组合经理。他曾负责所有领域（制药/生物制药行业、医疗技术和医疗用品、医疗服务的所有领域）的卫生保健投资。从1998年7月到2001年2月，他曾担任ING Barings公司的医疗保健投资银行全球主管。他也曾任职于Arstasis公司、Derma Sciences公司、MicroTherapeutics公司、Jomed公司、Photomedex公司、Pixelux Entertainment公司的董事会。他持有The Wharton School at the University of Pennsylvania的财务方向的工商管理硕士学位、Stanford University的工程科学硕士学位、The University of Texas at Austin的工程学士学位。
Samuel E. Navarro has served as our director since June 2019. Mr. Navarro also served as ViralClear's director from April 2020 until July 2020. Mr. Navarro has over 30 years of experience in investment banking, business development and medical technology. He currently serves as managing partner of Gravitas Healthcare, LLC, a strategic advisory/mergers and acquisition firm that specializes in emerging growth medical device companies. Since its founding in 2008 the firm has completed over 30 strategic medical device partnership transactions with some of the largest medical device companies in the industry. From 2005 through 2008 Mr. Navarro served as a managing director and global head of Medical Technology Investment Banking at Cowen & Company. From 2001 through 2005 Mr. Navarro served as a senior investment manager at The Galleon Group running the Galleon Healthcare Fund. From 1998 through 2001 he was global head of Healthcare Investment Banking at ING Barings, and prior to that, he was senior medical technology research analyst at UBS, Furman Selz and Needham & Company. From March 2014 to January 2017 Mr. Navarro served as a board director on the Audit and Nominating and Governance Committees of Derma Sciences, Inc. Since May 2018 Mr. Navarro has been serving on the board of directors of StrataSkin Sciences, Inc. and since 2019 as a member of their Audit Committee. Mr. Navarro serves or has served on the board of directors of other medical device companies, such as Arstasis, Dextera Surgical, Fixes-4-Kids, Jomed, MicroTherapeutics, and one non-medical company, Pixelux Entertainment. Mr. Navarro also served in the past as an advisory board member of OrthoPediatrics. Mr. Navarro received an MBA in finance from The Wharton School at the University of Pennsylvania. He also holds a master's degree in engineering from Stanford University and a bachelor's degree in engineering from the University of Texas at Austin. - Samuel E. Navarro，2014年3月以来，他曾一直担任我们的董事会成员。2008年10月以来，他一直担任Gravitas Healthcare公司（为医疗技术公司提供战略咨询服务）的管理合伙人。从2005年9月到2008年10月，他曾担任Cowen & Co.（位于纽约）的董事总经理，以及他们的医疗技术投资银行项目负责人，领导高级人团队，并负责建立所有产品类别（并购、咨询和融资服务和产品）的特许经营。从2001年到2005年，他曾任职The Galleon Group，经营the Galleon Healthcare Fund，担任高级投资组合经理。他曾负责所有领域（制药/生物制药行业、医疗技术和医疗用品、医疗服务的所有领域）的卫生保健投资。从1998年7月到2001年2月，他曾担任ING Barings公司的医疗保健投资银行全球主管。他也曾任职于Arstasis公司、Derma Sciences公司、MicroTherapeutics公司、Jomed公司、Photomedex公司、Pixelux Entertainment公司的董事会。他持有The Wharton School at the University of Pennsylvania的财务方向的工商管理硕士学位、Stanford University的工程科学硕士学位、The University of Texas at Austin的工程学士学位。
- Samuel E. Navarro has served as our director since June 2019. Mr. Navarro also served as ViralClear's director from April 2020 until July 2020. Mr. Navarro has over 30 years of experience in investment banking, business development and medical technology. He currently serves as managing partner of Gravitas Healthcare, LLC, a strategic advisory/mergers and acquisition firm that specializes in emerging growth medical device companies. Since its founding in 2008 the firm has completed over 30 strategic medical device partnership transactions with some of the largest medical device companies in the industry. From 2005 through 2008 Mr. Navarro served as a managing director and global head of Medical Technology Investment Banking at Cowen & Company. From 2001 through 2005 Mr. Navarro served as a senior investment manager at The Galleon Group running the Galleon Healthcare Fund. From 1998 through 2001 he was global head of Healthcare Investment Banking at ING Barings, and prior to that, he was senior medical technology research analyst at UBS, Furman Selz and Needham & Company. From March 2014 to January 2017 Mr. Navarro served as a board director on the Audit and Nominating and Governance Committees of Derma Sciences, Inc. Since May 2018 Mr. Navarro has been serving on the board of directors of StrataSkin Sciences, Inc. and since 2019 as a member of their Audit Committee. Mr. Navarro serves or has served on the board of directors of other medical device companies, such as Arstasis, Dextera Surgical, Fixes-4-Kids, Jomed, MicroTherapeutics, and one non-medical company, Pixelux Entertainment. Mr. Navarro also served in the past as an advisory board member of OrthoPediatrics. Mr. Navarro received an MBA in finance from The Wharton School at the University of Pennsylvania. He also holds a master's degree in engineering from Stanford University and a bachelor's degree in engineering from the University of Texas at Austin.
- Gregory D. Casciaro
-
Gregory D. Casciaro，2014年12月以来，他一直担任董事。2015年1月以来，他曾一直担任Apama Medical公司（一个医疗器械公司，专注于心房纤维性颤动技术）的董事会执行主席。他是QT Vascular公司（医疗设备公司）的董事（2001年以来）。从2010年6月到2014年8月，他曾担任AccessClosure公司（Cardinal Health收购的一个医疗设备公司）的总裁兼首席执行官。从2004年9月到2009年12月，他曾担任XTENT公司（Biosensors International Group公司收购的医疗设备公司）的总裁、首席执行官和董事。此前，他曾担任Orquest公司（一家私人公司，制造和销售骨科市场的生物治疗产品）的总裁、首席执行官和董事。此前，他曾担任AngioDynamics公司和Kerberos Proximal Solutions公司的董事。2001年之前，他曾担任General Surgical Innovations公司（从属于Tyco Healthcare Group的United States Surgical公司收购的腹腔镜手术设备制造商）的总裁、首席执行官和董事，也曾担任Vascular Intervention（从属于Guidant Corporation）、North American Instrument Corporation、Procter & Gamble Co. 的执行管理职务。他持有Marquette University的工商管理学士学位。他拥有丰富的任职成长型企业的首席执行管理经验，涉及医疗器械行业的兼并和收购。
Gregory D. Casciaro has been a director since December 2014. He has served as President and Chief Executive Officer of Cardiac Dimensions, a medical device company developing products to treat heart failure since December 2015. Since January 2015 Mr. Casciaro has served as executive chairman of the board of directors of Apama Medical, Inc., a medical device company focused on atrial fibrillation technologies. He has served as a director of QT Vascular Ltd., a medical device company, since 2001. From June 2010 to August 2014 Mr. Casciaro served as the President and Chief Executive Officer of AccessClosure, Inc., a medical device company that was acquired by Cardinal Health, Inc. From September 2004 to December 2009 he was the President, Chief Executive Officer and a director of XTENT, Inc., a medical device company that was acquired by Biosensors International Group, Ltd. Previously, Mr. Casciaro served as the President, Chief Executive Officer and a director of Orquest Inc., a private company manufacturing and selling bio-therapeutic products to the orthopedic market. Mr. Casciaro previously served as a director of AngioDynamics, Inc. and Kerberos Proximal Solutions. Prior to 2001 he was President, Chief Executive Officer and a director at General Surgical Innovations, Inc., a laparoscopic surgical equipment manufacturer that was acquired by United States Surgical, a division of Tyco Healthcare Group, and held executive and management positions at Vascular Intervention, a division of Guidant Corporation, North American Instrument Corporation, and Procter & Gamble Co. Mr. Casciaro graduated from Marquette University with a B.A. in Business Administration. Mr. Casciaro has extensive chief executive management experience with growth companies and in mergers and acquisitions in the medical device industry. - Gregory D. Casciaro，2014年12月以来，他一直担任董事。2015年1月以来，他曾一直担任Apama Medical公司（一个医疗器械公司，专注于心房纤维性颤动技术）的董事会执行主席。他是QT Vascular公司（医疗设备公司）的董事（2001年以来）。从2010年6月到2014年8月，他曾担任AccessClosure公司（Cardinal Health收购的一个医疗设备公司）的总裁兼首席执行官。从2004年9月到2009年12月，他曾担任XTENT公司（Biosensors International Group公司收购的医疗设备公司）的总裁、首席执行官和董事。此前，他曾担任Orquest公司（一家私人公司，制造和销售骨科市场的生物治疗产品）的总裁、首席执行官和董事。此前，他曾担任AngioDynamics公司和Kerberos Proximal Solutions公司的董事。2001年之前，他曾担任General Surgical Innovations公司（从属于Tyco Healthcare Group的United States Surgical公司收购的腹腔镜手术设备制造商）的总裁、首席执行官和董事，也曾担任Vascular Intervention（从属于Guidant Corporation）、North American Instrument Corporation、Procter & Gamble Co. 的执行管理职务。他持有Marquette University的工商管理学士学位。他拥有丰富的任职成长型企业的首席执行管理经验，涉及医疗器械行业的兼并和收购。
- Gregory D. Casciaro has been a director since December 2014. He has served as President and Chief Executive Officer of Cardiac Dimensions, a medical device company developing products to treat heart failure since December 2015. Since January 2015 Mr. Casciaro has served as executive chairman of the board of directors of Apama Medical, Inc., a medical device company focused on atrial fibrillation technologies. He has served as a director of QT Vascular Ltd., a medical device company, since 2001. From June 2010 to August 2014 Mr. Casciaro served as the President and Chief Executive Officer of AccessClosure, Inc., a medical device company that was acquired by Cardinal Health, Inc. From September 2004 to December 2009 he was the President, Chief Executive Officer and a director of XTENT, Inc., a medical device company that was acquired by Biosensors International Group, Ltd. Previously, Mr. Casciaro served as the President, Chief Executive Officer and a director of Orquest Inc., a private company manufacturing and selling bio-therapeutic products to the orthopedic market. Mr. Casciaro previously served as a director of AngioDynamics, Inc. and Kerberos Proximal Solutions. Prior to 2001 he was President, Chief Executive Officer and a director at General Surgical Innovations, Inc., a laparoscopic surgical equipment manufacturer that was acquired by United States Surgical, a division of Tyco Healthcare Group, and held executive and management positions at Vascular Intervention, a division of Guidant Corporation, North American Instrument Corporation, and Procter & Gamble Co. Mr. Casciaro graduated from Marquette University with a B.A. in Business Administration. Mr. Casciaro has extensive chief executive management experience with growth companies and in mergers and acquisitions in the medical device industry.
- R. Michael Kleine
-
R. Michael Kleine，2014年12月以来，他一直担任董事。他曾担任Miramar Labs公司（领先的医疗设备制造商）的总裁、首席执行官和董事（2014年2月以来）。此前，他曾担任EndoGastric Solutions公司（医疗设备制造商）的总裁兼首席执行官（从2011年5月到2014年2月），在那里他曾担任其董事会执行主席（直到2014年9月）。他也担任ASLAN Pharmaceuticals公司（制药公司）、QT Vascular公司（医疗设备公司）、BioParadox公司（一个医疗点生物治疗公司）的董事。任职EGS公司之前，他曾担任Biosensors International公司（公司专注于介入心脏病学和急救护理市场）的总裁、首席执行官和董事（从2008年1月到2010年11月）。此前，他曾担任Microvention公司（一个领先的医疗设备公司）的总裁兼首席执行官（直到Terumo Corporation被收购），期间他曾担任Microvention部门的总裁、首席执行官和主席。此前，他曾担任Pharos公司（公司专注于获取和开发核心技术）的合伙人，以及Thermo Cardiosystems公司（医疗设备制造商）、Sorin Biomedical公司（医疗设备制造商）的总裁兼首席执行官。他也曾担任Baxter International公司的多种领导职务。他持有Webster University的硕士学位，以及Missouri Valley College的生物科学学士学位。他拥有丰富的任职成长型企业的首席执行管理经验，涉及医疗器械行业的兼并和收购。
R. Michael Kleine has been a director since December 2014. He has served as President, Chief Executive Officer and a director of Miramar Labs, Inc., a leading medical device manufacturer, since February 2014. Previously, Mr. Kleine served as the President and Chief Executive Officer of EndoGastric Solutions, Inc., a medical device manufacturer, from May 2011 to February 2014 where he served as its executive chairman of the board until September 2014. Mr. Kleine also serves as a director of ASLAN Pharmaceuticals Pte. Ltd., a pharmaceutical company, QT Vascular, a medical device company, and BioParadox Inc., a point-of-care biologic treatment company. Prior to EGS, Mr. Kleine served as the President, Chief Executive Officer and as a director of Biosensors International, a company focused on the interventional cardiology and critical care markets, from January 2008 to November 2010. Previously, Mr. Kleine served as the President and Chief Executive Officer of Microvention, Inc., a leading medical device company, until its acquisition by Terumo Corporation, at which point Mr. Kleine served as the President, Chief Executive Officer and chairman of the Microvention Division. Previously, Mr. Kleine served as a partner of Pharos LLC, a company focused on acquiring and developing core technologies, and as President and Chief Executive Officer of each of Thermo Cardiosystems Inc. and Sorin Biomedical Inc., both medical device manufacturers. Mr. Kleine also held numerous leadership roles with Baxter International Inc. Mr. Kleine holds a M.S. from Webster University and a B.A. in biological science from Missouri Valley College. Mr. Kleine has extensive chief executive management experience with growth companies and mergers and acquisitions in the medical device industry. - R. Michael Kleine，2014年12月以来，他一直担任董事。他曾担任Miramar Labs公司（领先的医疗设备制造商）的总裁、首席执行官和董事（2014年2月以来）。此前，他曾担任EndoGastric Solutions公司（医疗设备制造商）的总裁兼首席执行官（从2011年5月到2014年2月），在那里他曾担任其董事会执行主席（直到2014年9月）。他也担任ASLAN Pharmaceuticals公司（制药公司）、QT Vascular公司（医疗设备公司）、BioParadox公司（一个医疗点生物治疗公司）的董事。任职EGS公司之前，他曾担任Biosensors International公司（公司专注于介入心脏病学和急救护理市场）的总裁、首席执行官和董事（从2008年1月到2010年11月）。此前，他曾担任Microvention公司（一个领先的医疗设备公司）的总裁兼首席执行官（直到Terumo Corporation被收购），期间他曾担任Microvention部门的总裁、首席执行官和主席。此前，他曾担任Pharos公司（公司专注于获取和开发核心技术）的合伙人，以及Thermo Cardiosystems公司（医疗设备制造商）、Sorin Biomedical公司（医疗设备制造商）的总裁兼首席执行官。他也曾担任Baxter International公司的多种领导职务。他持有Webster University的硕士学位，以及Missouri Valley College的生物科学学士学位。他拥有丰富的任职成长型企业的首席执行管理经验，涉及医疗器械行业的兼并和收购。
- R. Michael Kleine has been a director since December 2014. He has served as President, Chief Executive Officer and a director of Miramar Labs, Inc., a leading medical device manufacturer, since February 2014. Previously, Mr. Kleine served as the President and Chief Executive Officer of EndoGastric Solutions, Inc., a medical device manufacturer, from May 2011 to February 2014 where he served as its executive chairman of the board until September 2014. Mr. Kleine also serves as a director of ASLAN Pharmaceuticals Pte. Ltd., a pharmaceutical company, QT Vascular, a medical device company, and BioParadox Inc., a point-of-care biologic treatment company. Prior to EGS, Mr. Kleine served as the President, Chief Executive Officer and as a director of Biosensors International, a company focused on the interventional cardiology and critical care markets, from January 2008 to November 2010. Previously, Mr. Kleine served as the President and Chief Executive Officer of Microvention, Inc., a leading medical device company, until its acquisition by Terumo Corporation, at which point Mr. Kleine served as the President, Chief Executive Officer and chairman of the Microvention Division. Previously, Mr. Kleine served as a partner of Pharos LLC, a company focused on acquiring and developing core technologies, and as President and Chief Executive Officer of each of Thermo Cardiosystems Inc. and Sorin Biomedical Inc., both medical device manufacturers. Mr. Kleine also held numerous leadership roles with Baxter International Inc. Mr. Kleine holds a M.S. from Webster University and a B.A. in biological science from Missouri Valley College. Mr. Kleine has extensive chief executive management experience with growth companies and mergers and acquisitions in the medical device industry.
- Julian N. Nikolchev
-
Julian N. Nikolchev， 2015年10月15日加入Cardica，担任总裁、首席执行官兼董事；2014年至2015年间担任数家早期初创公司，SRI International和NanoDimension, Inc.（风险资本公司）的顾问；2007年至2014年间担任Pivot Medical（医疗器械公司，现为Stryker Sports Medicine的一部分）的创始人、首席执行官兼首席技术官，负责领导公司从发展型到一个有着最快发展整形市场份额品牌的纯商业化机构。他加入Pivot Medical，同时于2006年至2008年间担任Frazier Healthcare Ventures（风险资本公司）的创业合伙人。此前，他是CardioMind （出售给Biosensors International）的创始人、总裁兼首席执行官（2003-2006），AVAcore Technologies的总裁兼首席执行官（2000-2003），Pro*Duct Health（医疗器械公司，出售给Cytyc）的创始人兼总裁（1997-2000），Target Therapeutics（新兴创业集团）的经理（1991-1992），随后成立Conceptus （2014年出售给Bayer AG），并担任其多年的创始人兼首席技术官。在他进入医疗器械行业之前，他在工程机构担任了多个管理职位级别渐升。他获得了Stanford University的机械工程学士和硕士学位，以及the Massachusetts Institute of Technology的技术管理硕士学位。他是多篇技术商业化和新技术开发领域论文的作者，是超过35项已批准或待批准专利的发明人或联合发明人。
Julian N. Nikolchev joined Dextera as our President and Chief Executive Officer and Director on October 15 2015. From 2014 to 2015 he worked as a consultant for several early stage start-up companies, SRI International and NanoDimension, Inc., a Venture Capital firm. He previously served as founder, Chief Executive Officer and Chief Technology Officer of Pivot Medical, a medical device company now part of Stryker Sports Medicine from 2007 to 2014 where he was responsible for directing the transition from development enterprise to a full commercial organization with the leading brand in the fastest growing orthopedic market segment. He joined Pivot Medical while serving as a venture partner at Frazier Healthcare Ventures, a venture capital firm where he was a venture partner from 2006 to 2008. Before Frazier, he served as founder, president and Chief Executive Officer of CardioMind (sold to Biosensors International) from 2003 to 2006 and previously as president and Chief Executive Officer of AVAcore Technologies from 2000 to 2003 and as founder and president of Pro*Duct Health, a medical device company (sold to Cytyc) from 1997 to 2000. Prior to Pro*Duct Health, he served as manager of the new venture group at Target Therapeutics from 1991 to 1992 where he subsequently founded Conceptus (sold to Bayer AG in 2014) and served as founder and Chief Technology Officer for many years. Prior to his tenure leading medical device companies, Mr. Nikolchev served in a variety of escalating management positions within engineering organizations. He holds a B.S. and M.S. degrees in Mechanical Engineering from Stanford University and a M.S. degree in Management of Technology from the Massachusetts Institute of Technology. He is the author of numerous papers on technology commercialization and new technology development and an inventor and co-inventor on more than 35 issued or pending patents. Mr. Nikolchev has extensive experience in the medical device industry as a chief executive officer with a record of successfully leading management teams, managing products through the technical development process to commercialization and building successful companies that have been subsequently acquired by larger medical device companies. - Julian N. Nikolchev， 2015年10月15日加入Cardica，担任总裁、首席执行官兼董事；2014年至2015年间担任数家早期初创公司，SRI International和NanoDimension, Inc.（风险资本公司）的顾问；2007年至2014年间担任Pivot Medical（医疗器械公司，现为Stryker Sports Medicine的一部分）的创始人、首席执行官兼首席技术官，负责领导公司从发展型到一个有着最快发展整形市场份额品牌的纯商业化机构。他加入Pivot Medical，同时于2006年至2008年间担任Frazier Healthcare Ventures（风险资本公司）的创业合伙人。此前，他是CardioMind （出售给Biosensors International）的创始人、总裁兼首席执行官（2003-2006），AVAcore Technologies的总裁兼首席执行官（2000-2003），Pro*Duct Health（医疗器械公司，出售给Cytyc）的创始人兼总裁（1997-2000），Target Therapeutics（新兴创业集团）的经理（1991-1992），随后成立Conceptus （2014年出售给Bayer AG），并担任其多年的创始人兼首席技术官。在他进入医疗器械行业之前，他在工程机构担任了多个管理职位级别渐升。他获得了Stanford University的机械工程学士和硕士学位，以及the Massachusetts Institute of Technology的技术管理硕士学位。他是多篇技术商业化和新技术开发领域论文的作者，是超过35项已批准或待批准专利的发明人或联合发明人。
- Julian N. Nikolchev joined Dextera as our President and Chief Executive Officer and Director on October 15 2015. From 2014 to 2015 he worked as a consultant for several early stage start-up companies, SRI International and NanoDimension, Inc., a Venture Capital firm. He previously served as founder, Chief Executive Officer and Chief Technology Officer of Pivot Medical, a medical device company now part of Stryker Sports Medicine from 2007 to 2014 where he was responsible for directing the transition from development enterprise to a full commercial organization with the leading brand in the fastest growing orthopedic market segment. He joined Pivot Medical while serving as a venture partner at Frazier Healthcare Ventures, a venture capital firm where he was a venture partner from 2006 to 2008. Before Frazier, he served as founder, president and Chief Executive Officer of CardioMind (sold to Biosensors International) from 2003 to 2006 and previously as president and Chief Executive Officer of AVAcore Technologies from 2000 to 2003 and as founder and president of Pro*Duct Health, a medical device company (sold to Cytyc) from 1997 to 2000. Prior to Pro*Duct Health, he served as manager of the new venture group at Target Therapeutics from 1991 to 1992 where he subsequently founded Conceptus (sold to Bayer AG in 2014) and served as founder and Chief Technology Officer for many years. Prior to his tenure leading medical device companies, Mr. Nikolchev served in a variety of escalating management positions within engineering organizations. He holds a B.S. and M.S. degrees in Mechanical Engineering from Stanford University and a M.S. degree in Management of Technology from the Massachusetts Institute of Technology. He is the author of numerous papers on technology commercialization and new technology development and an inventor and co-inventor on more than 35 issued or pending patents. Mr. Nikolchev has extensive experience in the medical device industry as a chief executive officer with a record of successfully leading management teams, managing products through the technical development process to commercialization and building successful companies that have been subsequently acquired by larger medical device companies.
- Michael A. Bates
-
Michael A. Bates， 2015年12月被任命为Cardica的董事。他是一名独立金融高管、天使投资人及企业顾问，曾担任两家上市公司和两家私营企业的首席财务官。2008年7月至2015年9月，他是Moximed, Inc.（私营医疗器械公司，针对骨关节炎）的咨询首席财务官；2005年1月至2007年1月间担任St. Francis Medical Technologies, Inc.（医疗设备公司，2007年1月被Kyphon Inc.收购）的首席财务官；2000年4月至2004年10月间担任Silicon Genetics（复杂生物资料分析公司）的财务及行政副总裁兼首席财务官；1999年1月至2000年2月间担任Collagen Aesthetics, Inc.（医疗器械公司）的财务副总裁兼首席财务官；1995年至1998年间担任Penederm, Inc.（皮肤病制药公司）的多个财务相关职位， 最近担任其首席财务官。他此前是三家私营医疗器械公司的董事：B RRX Medical, Inc., Satiety, Inc.和Emphasys Medical, Inc. 他是一名注册会计师（失效），获得了California State University海沃德分校的工商管理学士学位，以及伯克利Haas School of Business at the University of California的金融学工商管理硕士学位。
Michael A. Bates was appointed as a director of Dextera in December 2015 and Chairman of the Board in January 2016. Mr. Bates is an independent financial executive, angel investor and company advisor, and was Chief Financial Officer of two public and two private companies in his operating career. From July 2008 until September 2015 Mr. Bates was the consulting Chief Financial Officer of Moximed, Inc., a private medical device company established to treat osteoarthritis. From January 2005 to January 2007 Mr. Bates served as Chief Financial Officer of St. Francis Medical Technologies, Inc., a medical device company, which was acquired by Kyphon Inc. in January 2007. From April 2000 to October 2004 Mr. Bates served as Vice President of Finance and Administration and Chief Financial Officer of Silicon Genetics, a bioinformatics company. From January 1999 to February 2000 Mr. Bates served as Vice President of Finance and Chief Financial Officer of Collagen Aesthetics, Inc., a medical device company. From 1995 to 1998 Mr. Bates served in various financial positions at Penederm, Inc., a dermatology pharmaceutical company, most recently as its Chief Financial Officer. Mr. Bates also serves on the boards of BÂRRX Medical, Inc., a privately-held medical device company, and Satiety, Inc., a privately-held company developing tools to treat obesity. Mr. Bates is a C.P.A., and holds a B.S. in Business Administration from California State University at Hayward and an M.B.A. in Finance from Haas School of Business at the University of California, Berkeley. Mr. Bates has extensive experience in emerging public and private medical device companies as a chief financial officer and in mergers and acquisitions in the medical device industry. - Michael A. Bates， 2015年12月被任命为Cardica的董事。他是一名独立金融高管、天使投资人及企业顾问，曾担任两家上市公司和两家私营企业的首席财务官。2008年7月至2015年9月，他是Moximed, Inc.（私营医疗器械公司，针对骨关节炎）的咨询首席财务官；2005年1月至2007年1月间担任St. Francis Medical Technologies, Inc.（医疗设备公司，2007年1月被Kyphon Inc.收购）的首席财务官；2000年4月至2004年10月间担任Silicon Genetics（复杂生物资料分析公司）的财务及行政副总裁兼首席财务官；1999年1月至2000年2月间担任Collagen Aesthetics, Inc.（医疗器械公司）的财务副总裁兼首席财务官；1995年至1998年间担任Penederm, Inc.（皮肤病制药公司）的多个财务相关职位， 最近担任其首席财务官。他此前是三家私营医疗器械公司的董事：B RRX Medical, Inc., Satiety, Inc.和Emphasys Medical, Inc. 他是一名注册会计师（失效），获得了California State University海沃德分校的工商管理学士学位，以及伯克利Haas School of Business at the University of California的金融学工商管理硕士学位。
- Michael A. Bates was appointed as a director of Dextera in December 2015 and Chairman of the Board in January 2016. Mr. Bates is an independent financial executive, angel investor and company advisor, and was Chief Financial Officer of two public and two private companies in his operating career. From July 2008 until September 2015 Mr. Bates was the consulting Chief Financial Officer of Moximed, Inc., a private medical device company established to treat osteoarthritis. From January 2005 to January 2007 Mr. Bates served as Chief Financial Officer of St. Francis Medical Technologies, Inc., a medical device company, which was acquired by Kyphon Inc. in January 2007. From April 2000 to October 2004 Mr. Bates served as Vice President of Finance and Administration and Chief Financial Officer of Silicon Genetics, a bioinformatics company. From January 1999 to February 2000 Mr. Bates served as Vice President of Finance and Chief Financial Officer of Collagen Aesthetics, Inc., a medical device company. From 1995 to 1998 Mr. Bates served in various financial positions at Penederm, Inc., a dermatology pharmaceutical company, most recently as its Chief Financial Officer. Mr. Bates also serves on the boards of BÂRRX Medical, Inc., a privately-held medical device company, and Satiety, Inc., a privately-held company developing tools to treat obesity. Mr. Bates is a C.P.A., and holds a B.S. in Business Administration from California State University at Hayward and an M.B.A. in Finance from Haas School of Business at the University of California, Berkeley. Mr. Bates has extensive experience in emerging public and private medical device companies as a chief financial officer and in mergers and acquisitions in the medical device industry.
- Thomas A. Afzal
-
Thomas A. Afzal，2015年1月以来，他一直担任董事。他曾担任Spinal Kinetics, Inc.（全球医疗设备公司）的总裁兼首席执行官（2003年共同创立公司以来）。他目前担任Heart Repair Technologies, Inc（他于2008年9月共同创立的公司，从事开发外科手术和经皮二尖瓣修复系统）的主席。他也曾担任PneumRx, Inc（公司致力于开发治疗肺气肿的创新技术）的主席（2011年7月至2015年1月公司出售给BTG plc LON：BTG）。从1997年到2003年，他担任CardioVention, Inc（医疗设备公司，专注于心血管手术的微创产品）的总裁和首席执行官。此前，他曾担任CardioThoracic Systems, Inc. （原为NASDAQ：CTSI，不停跳心脏手术产品的开发商）的心瓣膜集团的总经理，以及销售和营销副总裁。他曾任职Krauth Medical GmbH（一家民营欧洲领先的医疗设备经销商和制造商）、SulzerMedica（一个跨国医疗器械公司）、CarboMedics（领先的机械心脏瓣膜开发商和制造商）、Baxter International Inc.他目前担任Ivy Sports Medicine、Crosstrees Medical的董事会成员，也任职于the College of Business of San Diego State University的董事会。他获得圣地亚哥州立大学（San Diego State University）的工商管理学士学位。他拥有丰富的任职成长型企业的首席执行管理经验，包括建立一个医疗器械行业的重要欧洲业务、兼并和收购。
Thomas A. Afzal has been a director since January 2015. Mr. Afzal has served as the President and Chief Executive Officer of Spinal Kinetics, Inc., a global medical device company, since co-founding the company in 2003. Mr. Afzal also currently serves as the Chairman of Heart Repair Technologies, Inc., a company he co-founded in September 2008 that develops surgical and percutaneous mitral valve repair systems. He also served as the Chairman of PneumRx, Inc., a company dedicated to developing innovative technologies in treating emphysema, from July 2011 until it was sold to BTG plc LON:BTG in January 2015. From 1997 to 2003 Mr. Afzal served as the President and Chief Executive Officer of CardioVention, Inc., a medical device company he founded that was focused on minimal invasive products for cardiovascular surgery. Prior to that, Mr. Afzal served as the General Manager of the Cardiac Valve Group and Vice President of Sales and Marketing of CardioThoracic Systems, Inc. (formerly NASDAQ:CTSI), a developer of products for beating-heart surgery. Mr. Afzal's professional experience also includes positions with Krauth Medical GmbH, a privately-held leading European medical device distributor and manufacturer, SulzerMedica, a multi-national medical device company, CarboMedics, a leading developer and manufacturer of mechanical heart valves, and Baxter International Inc. Mr. Afzal also currently serves as a board member of Ivy Sports Medicine and Crosstrees Medical and also served on the board of the College of Business of San Diego State University. Mr. Afzal earned a Bachelor of Science Degree in Business Administration from San Diego State University. Mr. Afzal has extensive chief executive management experience with growth companies, including establishing a significant European business presence, and mergers and acquisitions in the medical device industry. - Thomas A. Afzal，2015年1月以来，他一直担任董事。他曾担任Spinal Kinetics, Inc.（全球医疗设备公司）的总裁兼首席执行官（2003年共同创立公司以来）。他目前担任Heart Repair Technologies, Inc（他于2008年9月共同创立的公司，从事开发外科手术和经皮二尖瓣修复系统）的主席。他也曾担任PneumRx, Inc（公司致力于开发治疗肺气肿的创新技术）的主席（2011年7月至2015年1月公司出售给BTG plc LON：BTG）。从1997年到2003年，他担任CardioVention, Inc（医疗设备公司，专注于心血管手术的微创产品）的总裁和首席执行官。此前，他曾担任CardioThoracic Systems, Inc. （原为NASDAQ：CTSI，不停跳心脏手术产品的开发商）的心瓣膜集团的总经理，以及销售和营销副总裁。他曾任职Krauth Medical GmbH（一家民营欧洲领先的医疗设备经销商和制造商）、SulzerMedica（一个跨国医疗器械公司）、CarboMedics（领先的机械心脏瓣膜开发商和制造商）、Baxter International Inc.他目前担任Ivy Sports Medicine、Crosstrees Medical的董事会成员，也任职于the College of Business of San Diego State University的董事会。他获得圣地亚哥州立大学（San Diego State University）的工商管理学士学位。他拥有丰富的任职成长型企业的首席执行管理经验，包括建立一个医疗器械行业的重要欧洲业务、兼并和收购。
- Thomas A. Afzal has been a director since January 2015. Mr. Afzal has served as the President and Chief Executive Officer of Spinal Kinetics, Inc., a global medical device company, since co-founding the company in 2003. Mr. Afzal also currently serves as the Chairman of Heart Repair Technologies, Inc., a company he co-founded in September 2008 that develops surgical and percutaneous mitral valve repair systems. He also served as the Chairman of PneumRx, Inc., a company dedicated to developing innovative technologies in treating emphysema, from July 2011 until it was sold to BTG plc LON:BTG in January 2015. From 1997 to 2003 Mr. Afzal served as the President and Chief Executive Officer of CardioVention, Inc., a medical device company he founded that was focused on minimal invasive products for cardiovascular surgery. Prior to that, Mr. Afzal served as the General Manager of the Cardiac Valve Group and Vice President of Sales and Marketing of CardioThoracic Systems, Inc. (formerly NASDAQ:CTSI), a developer of products for beating-heart surgery. Mr. Afzal's professional experience also includes positions with Krauth Medical GmbH, a privately-held leading European medical device distributor and manufacturer, SulzerMedica, a multi-national medical device company, CarboMedics, a leading developer and manufacturer of mechanical heart valves, and Baxter International Inc. Mr. Afzal also currently serves as a board member of Ivy Sports Medicine and Crosstrees Medical and also served on the board of the College of Business of San Diego State University. Mr. Afzal earned a Bachelor of Science Degree in Business Administration from San Diego State University. Mr. Afzal has extensive chief executive management experience with growth companies, including establishing a significant European business presence, and mergers and acquisitions in the medical device industry.
高管简历
中英对照 | 中文 | 英文- Liam J. Burns
Liam J. Burns，2014年1月加入Cardica，担任本公司的销售与营销副总裁。2007年9月起，他担任EP Burns Group LLC的总裁，这是专注于医疗保健、生命科学行业的销售、营销、领导力开发咨询公司；他是该公司的创始人，负责所有业务。2006年9月至2007年8月，他担任外科缝合公司Power Medical Interventions的营销副总裁。1991年10月至2006年8月，他在Johnson & Johnson旗下的Ethicon, Inc担任过各种销售营销职务。他在College of Holy Cross获得学士学位，在Case Western Reserve University获得工商管理硕士学位。
Liam J. Burns joined Dextera Surgical as our Vice President, Sales and Marketing in January 2014. Since September 2007 he has been President of EP Burns Group LLC, a healthcare and life science focused sales, marketing and leadership development consulting company that he founded, at which he was responsible for all facets of the business. From September 2006 to August 2007 he was Vice President Marketing of Power Medical Interventions, Inc. a surgical stapling company. From October 1991 to August 2006 he held various sales and marketing management positions with Ethicon, Inc., a Johnson & Johnson company. Mr. Burns holds a B.A. degree from the College of Holy Cross and an M.B.A. degree from Case Western Reserve University.- Liam J. Burns，2014年1月加入Cardica，担任本公司的销售与营销副总裁。2007年9月起，他担任EP Burns Group LLC的总裁，这是专注于医疗保健、生命科学行业的销售、营销、领导力开发咨询公司；他是该公司的创始人，负责所有业务。2006年9月至2007年8月，他担任外科缝合公司Power Medical Interventions的营销副总裁。1991年10月至2006年8月，他在Johnson & Johnson旗下的Ethicon, Inc担任过各种销售营销职务。他在College of Holy Cross获得学士学位，在Case Western Reserve University获得工商管理硕士学位。
- Liam J. Burns joined Dextera Surgical as our Vice President, Sales and Marketing in January 2014. Since September 2007 he has been President of EP Burns Group LLC, a healthcare and life science focused sales, marketing and leadership development consulting company that he founded, at which he was responsible for all facets of the business. From September 2006 to August 2007 he was Vice President Marketing of Power Medical Interventions, Inc. a surgical stapling company. From October 1991 to August 2006 he held various sales and marketing management positions with Ethicon, Inc., a Johnson & Johnson company. Mr. Burns holds a B.A. degree from the College of Holy Cross and an M.B.A. degree from Case Western Reserve University.
- Gregory P. Watson
Gregory P. Watson，他于2015年5月加入Cardica公司，担任我们的运营副总裁。从2013年3月到2015年5月，他曾建议初创公司和中期发展阶段的医疗设备公司，涉及建立和扩大它们制造业务的商业化的不同阶段。从2010年7月到2013年1月，他曾担任Uptake Medical Corp.的制造、运营和产品开发副总裁，在那里他负责提供产品开发和制造领域的领导和方向。从1999年到2010年，他曾担任TherOx公司的制造和产品开发副总裁。从1987年到1999年，他曾任职Baxter Healthcare Corporation12年，在那里他曾担任心血管部门的多种职务，包括运营总监、研发总监和工厂经理。他目前拥有9项美国专利。他持有California State Polytechnic University的工业管理学士学位。
Gregory P. Watson joined Dextera Surgical as our Vice President of Operations in May 2015. From March 2013 to May 2015 Mr. Watson consulted for start-up and mid-stage medical device firms in various stages of commercialization to establish and scale up their manufacturing operations. From July 2010 to January 2013 Mr. Watson held the positions of vice president of manufacturing, operations and product development for Uptake Medical Corp., where he was responsible for providing leadership and direction for the product development and manufacturing areas. From 1999 to 2010 Mr. Watson served as vice president of manufacturing and product development for TherOx, Inc. From 1987 to 1999 Mr. Watson served twelve years at Baxter Healthcare Corporation where he held various positions in the cardiovascular division including director of operations, director of R&D and plant manager. He currently holds nine U.S. patents. Mr. Watson earned his B.S. in Industrial Management from California State Polytechnic University.- Gregory P. Watson，他于2015年5月加入Cardica公司，担任我们的运营副总裁。从2013年3月到2015年5月，他曾建议初创公司和中期发展阶段的医疗设备公司，涉及建立和扩大它们制造业务的商业化的不同阶段。从2010年7月到2013年1月，他曾担任Uptake Medical Corp.的制造、运营和产品开发副总裁，在那里他负责提供产品开发和制造领域的领导和方向。从1999年到2010年，他曾担任TherOx公司的制造和产品开发副总裁。从1987年到1999年，他曾任职Baxter Healthcare Corporation12年，在那里他曾担任心血管部门的多种职务，包括运营总监、研发总监和工厂经理。他目前拥有9项美国专利。他持有California State Polytechnic University的工业管理学士学位。
- Gregory P. Watson joined Dextera Surgical as our Vice President of Operations in May 2015. From March 2013 to May 2015 Mr. Watson consulted for start-up and mid-stage medical device firms in various stages of commercialization to establish and scale up their manufacturing operations. From July 2010 to January 2013 Mr. Watson held the positions of vice president of manufacturing, operations and product development for Uptake Medical Corp., where he was responsible for providing leadership and direction for the product development and manufacturing areas. From 1999 to 2010 Mr. Watson served as vice president of manufacturing and product development for TherOx, Inc. From 1987 to 1999 Mr. Watson served twelve years at Baxter Healthcare Corporation where he held various positions in the cardiovascular division including director of operations, director of R&D and plant manager. He currently holds nine U.S. patents. Mr. Watson earned his B.S. in Industrial Management from California State Polytechnic University.
- Julian N. Nikolchev
Julian N. Nikolchev， 2015年10月15日加入Cardica，担任总裁、首席执行官兼董事；2014年至2015年间担任数家早期初创公司，SRI International和NanoDimension, Inc.（风险资本公司）的顾问；2007年至2014年间担任Pivot Medical（医疗器械公司，现为Stryker Sports Medicine的一部分）的创始人、首席执行官兼首席技术官，负责领导公司从发展型到一个有着最快发展整形市场份额品牌的纯商业化机构。他加入Pivot Medical，同时于2006年至2008年间担任Frazier Healthcare Ventures（风险资本公司）的创业合伙人。此前，他是CardioMind （出售给Biosensors International）的创始人、总裁兼首席执行官（2003-2006），AVAcore Technologies的总裁兼首席执行官（2000-2003），Pro*Duct Health（医疗器械公司，出售给Cytyc）的创始人兼总裁（1997-2000），Target Therapeutics（新兴创业集团）的经理（1991-1992），随后成立Conceptus （2014年出售给Bayer AG），并担任其多年的创始人兼首席技术官。在他进入医疗器械行业之前，他在工程机构担任了多个管理职位级别渐升。他获得了Stanford University的机械工程学士和硕士学位，以及the Massachusetts Institute of Technology的技术管理硕士学位。他是多篇技术商业化和新技术开发领域论文的作者，是超过35项已批准或待批准专利的发明人或联合发明人。
Julian N. Nikolchev joined Dextera as our President and Chief Executive Officer and Director on October 15 2015. From 2014 to 2015 he worked as a consultant for several early stage start-up companies, SRI International and NanoDimension, Inc., a Venture Capital firm. He previously served as founder, Chief Executive Officer and Chief Technology Officer of Pivot Medical, a medical device company now part of Stryker Sports Medicine from 2007 to 2014 where he was responsible for directing the transition from development enterprise to a full commercial organization with the leading brand in the fastest growing orthopedic market segment. He joined Pivot Medical while serving as a venture partner at Frazier Healthcare Ventures, a venture capital firm where he was a venture partner from 2006 to 2008. Before Frazier, he served as founder, president and Chief Executive Officer of CardioMind (sold to Biosensors International) from 2003 to 2006 and previously as president and Chief Executive Officer of AVAcore Technologies from 2000 to 2003 and as founder and president of Pro*Duct Health, a medical device company (sold to Cytyc) from 1997 to 2000. Prior to Pro*Duct Health, he served as manager of the new venture group at Target Therapeutics from 1991 to 1992 where he subsequently founded Conceptus (sold to Bayer AG in 2014) and served as founder and Chief Technology Officer for many years. Prior to his tenure leading medical device companies, Mr. Nikolchev served in a variety of escalating management positions within engineering organizations. He holds a B.S. and M.S. degrees in Mechanical Engineering from Stanford University and a M.S. degree in Management of Technology from the Massachusetts Institute of Technology. He is the author of numerous papers on technology commercialization and new technology development and an inventor and co-inventor on more than 35 issued or pending patents. Mr. Nikolchev has extensive experience in the medical device industry as a chief executive officer with a record of successfully leading management teams, managing products through the technical development process to commercialization and building successful companies that have been subsequently acquired by larger medical device companies.- Julian N. Nikolchev， 2015年10月15日加入Cardica，担任总裁、首席执行官兼董事；2014年至2015年间担任数家早期初创公司，SRI International和NanoDimension, Inc.（风险资本公司）的顾问；2007年至2014年间担任Pivot Medical（医疗器械公司，现为Stryker Sports Medicine的一部分）的创始人、首席执行官兼首席技术官，负责领导公司从发展型到一个有着最快发展整形市场份额品牌的纯商业化机构。他加入Pivot Medical，同时于2006年至2008年间担任Frazier Healthcare Ventures（风险资本公司）的创业合伙人。此前，他是CardioMind （出售给Biosensors International）的创始人、总裁兼首席执行官（2003-2006），AVAcore Technologies的总裁兼首席执行官（2000-2003），Pro*Duct Health（医疗器械公司，出售给Cytyc）的创始人兼总裁（1997-2000），Target Therapeutics（新兴创业集团）的经理（1991-1992），随后成立Conceptus （2014年出售给Bayer AG），并担任其多年的创始人兼首席技术官。在他进入医疗器械行业之前，他在工程机构担任了多个管理职位级别渐升。他获得了Stanford University的机械工程学士和硕士学位，以及the Massachusetts Institute of Technology的技术管理硕士学位。他是多篇技术商业化和新技术开发领域论文的作者，是超过35项已批准或待批准专利的发明人或联合发明人。
- Julian N. Nikolchev joined Dextera as our President and Chief Executive Officer and Director on October 15 2015. From 2014 to 2015 he worked as a consultant for several early stage start-up companies, SRI International and NanoDimension, Inc., a Venture Capital firm. He previously served as founder, Chief Executive Officer and Chief Technology Officer of Pivot Medical, a medical device company now part of Stryker Sports Medicine from 2007 to 2014 where he was responsible for directing the transition from development enterprise to a full commercial organization with the leading brand in the fastest growing orthopedic market segment. He joined Pivot Medical while serving as a venture partner at Frazier Healthcare Ventures, a venture capital firm where he was a venture partner from 2006 to 2008. Before Frazier, he served as founder, president and Chief Executive Officer of CardioMind (sold to Biosensors International) from 2003 to 2006 and previously as president and Chief Executive Officer of AVAcore Technologies from 2000 to 2003 and as founder and president of Pro*Duct Health, a medical device company (sold to Cytyc) from 1997 to 2000. Prior to Pro*Duct Health, he served as manager of the new venture group at Target Therapeutics from 1991 to 1992 where he subsequently founded Conceptus (sold to Bayer AG in 2014) and served as founder and Chief Technology Officer for many years. Prior to his tenure leading medical device companies, Mr. Nikolchev served in a variety of escalating management positions within engineering organizations. He holds a B.S. and M.S. degrees in Mechanical Engineering from Stanford University and a M.S. degree in Management of Technology from the Massachusetts Institute of Technology. He is the author of numerous papers on technology commercialization and new technology development and an inventor and co-inventor on more than 35 issued or pending patents. Mr. Nikolchev has extensive experience in the medical device industry as a chief executive officer with a record of successfully leading management teams, managing products through the technical development process to commercialization and building successful companies that have been subsequently acquired by larger medical device companies.
- Thomas J. Palermo
Thomas J. Palermo，2015年11月加入Cardica担任首席运营官，将其近30年的医疗设备开发和管理专业知识带到Cardica，最近担任UlceRx（慢性伤口护理初创公司）的代理首席执行官，负责监管公司业务的各个方面。在进入UlceRx之前，他是ReVascular Therapeutics（2011年被Boston Scientific收购）的总裁兼首席执行官，负责监管公司业务的各个方面，并优化技术平台以满足市场对the TruePath CTO Device system的需求。在进入 ReVascular Therapeutics之前，他担任了Ensure Medical的运营兼工程副总裁，负责ExoSeal生物可吸收股骨闭合装置的监管、临床、质量控制、研发和运营。此前，他担任了多家医疗设备企业的工程、运营、研发和业务开发相关的多个职位。他获得了New Hampshire College的技术管理学士学位，持有或已申请40余项专利。
Thomas J. Palermo joined Dextera as our Chief Operating Officer in November 2015. Most recently, he served as acting CEO of UlceRx, a start-up chronic wound care company, where he was responsible for overseeing all aspects of the company’s business. Prior to UlceRx, Mr. Palermo was president and CEO of ReVascular Therapeutics acquired by Boston Scientific in 2011 where he was responsible for overseeing all aspects of the company’s business and where he revamped the technology platform to meet the market demand for the TruePath CTO Device system. Prior to ReVascular Therapeutics, he served as vice president of operations and engineering at Ensure Medical where he was responsible for regulatory, clinical, quality assurance, research and development and operations for the development of ExoSeal bio-absorbable femoral closure device. Prior to Ensure Medical, he served in a variety of escalating roles related to engineering, operations, research and development and business development at a variety of medical device companies. He received his B.S. degree in Technical Management from New Hampshire College and holds more than 40 issued and pending patents.- Thomas J. Palermo，2015年11月加入Cardica担任首席运营官，将其近30年的医疗设备开发和管理专业知识带到Cardica，最近担任UlceRx（慢性伤口护理初创公司）的代理首席执行官，负责监管公司业务的各个方面。在进入UlceRx之前，他是ReVascular Therapeutics（2011年被Boston Scientific收购）的总裁兼首席执行官，负责监管公司业务的各个方面，并优化技术平台以满足市场对the TruePath CTO Device system的需求。在进入 ReVascular Therapeutics之前，他担任了Ensure Medical的运营兼工程副总裁，负责ExoSeal生物可吸收股骨闭合装置的监管、临床、质量控制、研发和运营。此前，他担任了多家医疗设备企业的工程、运营、研发和业务开发相关的多个职位。他获得了New Hampshire College的技术管理学士学位，持有或已申请40余项专利。
- Thomas J. Palermo joined Dextera as our Chief Operating Officer in November 2015. Most recently, he served as acting CEO of UlceRx, a start-up chronic wound care company, where he was responsible for overseeing all aspects of the company’s business. Prior to UlceRx, Mr. Palermo was president and CEO of ReVascular Therapeutics acquired by Boston Scientific in 2011 where he was responsible for overseeing all aspects of the company’s business and where he revamped the technology platform to meet the market demand for the TruePath CTO Device system. Prior to ReVascular Therapeutics, he served as vice president of operations and engineering at Ensure Medical where he was responsible for regulatory, clinical, quality assurance, research and development and operations for the development of ExoSeal bio-absorbable femoral closure device. Prior to Ensure Medical, he served in a variety of escalating roles related to engineering, operations, research and development and business development at a variety of medical device companies. He received his B.S. degree in Technical Management from New Hampshire College and holds more than 40 issued and pending patents.
- Robert Y. Newell
Robert Y. Newell，他于2018年10月被任命为Mosys, Inc.的董事。他目前是新兴技术和医疗保健公司的顾问和顾问，曾在硅谷的技术和医疗保健公司担任财务管理职位超过25年。从2003年到2018年，Newell先生担任Dextera Surgical Inc.（高级订书机设备和自动化医疗系统的开发商）的首席财务官。2017年12月，在达成协议出售其全部资产后，Dextera Surgical, Inc.根据美国法典第11篇第11章，向特拉华州地区的美国破产法院提交了自愿重组申请。2012年至2017年，Newell先生担任ARI Network Services, Inc.（SaaS和数据即服务解决方案的领先供应商）的董事会成员。此前，Newell先生担任Omnicell, Inc.（一家医院供应和药物管理公司）的首席财务官，并担任Beta Group, LLC和Cardiometrics, Inc.的执行职务。在他的商业生涯之前，他是美国空军的飞行员。他持有the College of William & Mary的数学学士学位和Harvard Business School的工商管理硕士学位。
Robert Y. Newell,has served as a member of Peraso Inc. board of directors since October 2018 and is currently a consultant and advisor to emerging technology and healthcare companies. He has held financial management positions for companies in Silicon Valley for over 25 years. From 2003 to 2018, Mr. Newell was chief financial officer of Dextera Surgical, Inc. (Dextera) a developer of advanced surgical stapling and medical devices. In December 2017, after entering into an agreement to sell substantially all of its assets, Dextera filed a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware. He served on the board of directors of ARI Network Services, a leading publicly traded supplier of SaaS and data as a service solutions. Previously, Mr. Newell served as chief financial officer of Omnicell, an automated medication and hospital supply management company, and prior to 2000, he held executive positions with the Beta Group and Cardiometrics. Prior to his business career, he was a pilot in the United States Air Force. Mr. Newell holds a B.A. in mathematics from the College of William & Mary and an MBA from Harvard Business School.- Robert Y. Newell，他于2018年10月被任命为Mosys, Inc.的董事。他目前是新兴技术和医疗保健公司的顾问和顾问，曾在硅谷的技术和医疗保健公司担任财务管理职位超过25年。从2003年到2018年，Newell先生担任Dextera Surgical Inc.（高级订书机设备和自动化医疗系统的开发商）的首席财务官。2017年12月，在达成协议出售其全部资产后，Dextera Surgical, Inc.根据美国法典第11篇第11章，向特拉华州地区的美国破产法院提交了自愿重组申请。2012年至2017年，Newell先生担任ARI Network Services, Inc.（SaaS和数据即服务解决方案的领先供应商）的董事会成员。此前，Newell先生担任Omnicell, Inc.（一家医院供应和药物管理公司）的首席财务官，并担任Beta Group, LLC和Cardiometrics, Inc.的执行职务。在他的商业生涯之前，他是美国空军的飞行员。他持有the College of William & Mary的数学学士学位和Harvard Business School的工商管理硕士学位。
- Robert Y. Newell,has served as a member of Peraso Inc. board of directors since October 2018 and is currently a consultant and advisor to emerging technology and healthcare companies. He has held financial management positions for companies in Silicon Valley for over 25 years. From 2003 to 2018, Mr. Newell was chief financial officer of Dextera Surgical, Inc. (Dextera) a developer of advanced surgical stapling and medical devices. In December 2017, after entering into an agreement to sell substantially all of its assets, Dextera filed a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware. He served on the board of directors of ARI Network Services, a leading publicly traded supplier of SaaS and data as a service solutions. Previously, Mr. Newell served as chief financial officer of Omnicell, an automated medication and hospital supply management company, and prior to 2000, he held executive positions with the Beta Group and Cardiometrics. Prior to his business career, he was a pilot in the United States Air Force. Mr. Newell holds a B.A. in mathematics from the College of William & Mary and an MBA from Harvard Business School.
- Robert Y. Newell
Robert Y. Newell，2003年3月起，他担任我们的财务部副总裁和首席财务官；2005年7月至2008年7月，他是财务部和运营部副总裁；2000年1月至2003年2月，他是Omnicell（医院供应和药物管理公司）财务部副总裁和首席财务官。他获有College of William & Mary数学学士学位以及哈佛商学院工商管理硕士学位。目前，他是ARI Network Services（公共软件技术公司）董事会成员。
Robert Y. Newell has been our Vice President, Finance and Chief Financial Officer since March 2003 and was Vice President, Finance and Operations, from July 2005 to July 2008. From January 2000 to February 2003 he was Vice President, Finance and Chief Financial Officer for Omnicell, Inc., a hospital supply and medication management company. Mr. Newell was also a director of ARI Network Services, Inc., a software as a service company, until it was acquired in August 2017. Mr. Newell holds a B.A. degree in Mathematics from the College of William & Mary and an M.B.A. degree from the Harvard Business School.- Robert Y. Newell，2003年3月起，他担任我们的财务部副总裁和首席财务官；2005年7月至2008年7月，他是财务部和运营部副总裁；2000年1月至2003年2月，他是Omnicell（医院供应和药物管理公司）财务部副总裁和首席财务官。他获有College of William & Mary数学学士学位以及哈佛商学院工商管理硕士学位。目前，他是ARI Network Services（公共软件技术公司）董事会成员。
- Robert Y. Newell has been our Vice President, Finance and Chief Financial Officer since March 2003 and was Vice President, Finance and Operations, from July 2005 to July 2008. From January 2000 to February 2003 he was Vice President, Finance and Chief Financial Officer for Omnicell, Inc., a hospital supply and medication management company. Mr. Newell was also a director of ARI Network Services, Inc., a software as a service company, until it was acquired in August 2017. Mr. Newell holds a B.A. degree in Mathematics from the College of William & Mary and an M.B.A. degree from the Harvard Business School.